drugset
drugset / Trial / NCT06245018

A Trial to Evaluate the Safety and Preliminary Efficacy of iNK in the Treatment of Subjects With Solid Tumor

NCT06245018 ↗

Not yet recruiting 50 enrolled Nuwacell Biotechnologies Co., Ltd.
NaSequentialOpen-labelTreatment

Summary

This trial is to investigate the safety, efficacy of iNK in subjects with solid tumor. It is a dose escalation and extension trial.

Timeline

Start
2024-02-01
Primary completion
2027-03-01
Completion
2030-03-01

Drugs

EvaluationDrugModalityDoseRoute
Subject iNK Cell therapy — —

Indications

neoplasm